Other Events ·
Evaxion to present new target validation data for EVX-04 AML vaccine at ASH 2026
EVAXEvaxion A/S
Evaxion will present new preclinical target validation data for EVX-04, an off-the-shelf therapeutic DNA vaccine for acute myeloid leukemia (AML), in a poster session at the American Society of Hematology (ASH) Annual Meeting. The presentation, scheduled for December 13, 2026, details conserved endogenous retrovirus targets identified via the company's AI-Immunology platform and demonstrates broad patient coverage and immune response induction in humanized mice. Evaxion is a clinical-stage TechBio company developing novel immunotherapies using artificial intelligence.